Promis Neurosciences (NASDAQ:PMN), Inc. (NASDAQ: PMN) is a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies for central nervous system autoimmune and neuroinflammatory diseases. The company’s lead product candidate, PMN310, is a monoclonal antibody engineered to bind a protective epitope on myelin oligodendrocyte glycoprotein (MOG), aiming to neutralize pathogenic autoantibodies while preserving normal immune function. In addition to its multiple sclerosis program, Promis Neurosciences has discovery-stage initiatives targeting neuromyelitis optica spectrum disorder and related conditions that result from autoreactive immune responses in the brain and spinal cord.
Founded in 2017 by a team of immunologists from leading academic institutions, the company leverages a proprietary platform that isolates naturally occurring protective autoantibodies from patient samples. Through high-throughput screening and epitope-mapping technologies, Promis Neurosciences identifies and engineers candidate molecules that offer precision immunomodulation. This bottom-up approach is designed to reduce off-target effects commonly associated with broad-spectrum immunosuppression, potentially improving both safety and long-term efficacy for patients.
Headquartered in Cambridge, Massachusetts, Promis Neurosciences operates additional research and development facilities in Vancouver, Canada, and Zurich, Switzerland. The company collaborates with leading academic centers and patient advocacy organizations across North America and Europe to support clinical trial design, patient recruitment and regulatory interactions. Its global footprint enables concurrent Phase 1/2 studies and lays the groundwork for future filings in multiple regulatory jurisdictions.
Led by CEO Dan Schneider, who brings extensive experience from senior roles at Genentech and Biogen, the management team combines deep expertise in neuroimmunology, biologics manufacturing and strategic commercialization. The scientific advisory board includes prominent neurologists and immunologists who guide the company’s research priorities. Together, Promis Neurosciences aims to transform the treatment landscape for autoimmune and neurodegenerative diseases by delivering targeted, disease-modifying therapies.
